Celcuity launches REVTORPYK commercially in US for HR+/HER2- advanced breast cancer

Celcuity announced REVTORPYK is now commercially available in the U.S. for eligible HR+/HER2- advanced breast cancer patients without a PIK3CA mutation.Key Highlights:Original SEC Filing: Celcuity Inc. [ CELC ] - 8-K - Sep. 30, 2026This is an AI-powered summary. It may contain inaccuracies. Conside…